Reducing financial toxicity in bladder cancer care.

dc.contributor.author

Kurnot, Jeremy A

dc.contributor.author

Kaye, Deborah R

dc.date.accessioned

2025-11-15T00:55:18Z

dc.date.available

2025-11-15T00:55:18Z

dc.date.issued

2024-11

dc.description.abstract

Purpose of review

Financial toxicity is a significant concern for many individuals with bladder cancer, which is, overall, the most expensive malignancy, per patient. Financial toxicity, defined as the harmful effects of treatment costs on an individual's quality of life, is associated with worse outcomes and decreased quality of life. Awareness of the objective and subjective factors that contribute to financial toxicity, and ways to mitigate their effects on patients, is essential to reduce the burden of bladder cancer care. This commentary aims to discuss the elements contributing to financial toxicity amongst bladder cancer patients, identify at-risk populations, and review current and potential strategies for mitigating financial burden.

Recent findings

Bladder cancer is becoming more expensive as the use of novel therapies increases. Early data suggest how some of these novel treatments or changes in treatment delivery may impact costs. Potential innovative strategies for cost reduction include blue light cystoscopy, intravesical gemcitabine-docetaxel rather than BCG for high-risk nonmuscle-invasive patients, home BCG therapy, and surveillance guideline optimization. However, there is still much work to be done on the potential impacts of these treatment on financial toxicity. While there is a paucity of data on treatment changes to reduce financial toxicity, and cost data can be hard to access, clinicians can still reduce the financial burden of cancer care. Awareness, financial toxicity screening, cost communication, and/or early referral to financial navigators or other similar resources have the potential to reduce financial burden. Despite mounting evidence, these tools/techniques are largely underutilized.

Summary

Many individuals with bladder cancer face significant financial toxicity, with the potential for this to worsen in the setting of rising treatment costs. Novel diagnostic and treatment modifications may reduce financial toxicity. However, awareness, screening, cost discussions, and utilization of financial navigators are tools/techniques that are currently available and should be used to reduce financial burden.
dc.identifier

00042307-202411000-00015

dc.identifier.issn

0963-0643

dc.identifier.issn

1473-6586

dc.identifier.uri

https://hdl.handle.net/10161/33519

dc.language

eng

dc.publisher

Ovid Technologies (Wolters Kluwer Health)

dc.relation.ispartof

Current opinion in urology

dc.relation.isversionof

10.1097/mou.0000000000001218

dc.rights.uri

https://creativecommons.org/licenses/by-nc/4.0

dc.subject

Humans

dc.subject

Cost of Illness

dc.subject

Quality of Life

dc.subject

Health Care Costs

dc.subject

Urinary Bladder Neoplasms

dc.title

Reducing financial toxicity in bladder cancer care.

dc.type

Journal article

pubs.begin-page

484

pubs.end-page

488

pubs.issue

6

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Staff

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Surgery

pubs.publication-status

Published

pubs.volume

34

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Reducing financial toxicity in bladder cancer care.pdf
Size:
61.06 KB
Format:
Adobe Portable Document Format